EP1080183A1 - Promotion de la differenciation cellulaire par des cellules ayant subi initialement plusieurs passages - Google Patents

Promotion de la differenciation cellulaire par des cellules ayant subi initialement plusieurs passages

Info

Publication number
EP1080183A1
EP1080183A1 EP99928354A EP99928354A EP1080183A1 EP 1080183 A1 EP1080183 A1 EP 1080183A1 EP 99928354 A EP99928354 A EP 99928354A EP 99928354 A EP99928354 A EP 99928354A EP 1080183 A1 EP1080183 A1 EP 1080183A1
Authority
EP
European Patent Office
Prior art keywords
cells
reaggregated
insulin
islet
passaged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99928354A
Other languages
German (de)
English (en)
Inventor
Ivan T. Todorov
Kelly I. Scheying
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Desmos Inc
Original Assignee
Desmos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Desmos Inc filed Critical Desmos Inc
Publication of EP1080183A1 publication Critical patent/EP1080183A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/22—Coculture with; Conditioned medium produced by pancreatic cells

Definitions

  • the present invention relates to promotion of cell differentiation. More specifically, the invention relates to the ability of initially passaged (PO) differentiated cells to induce the differentiation of expanded passaged cells.
  • PO initially passaged
  • Cell differentiation is a process which occurs in the blood, tissues and organs in which a cell population develops a specialized form, character or function differing from that or surrounding cell types.
  • marrow stromal cells are undifferentiated precursor cells which become bone-forming cells called osteoblasts, plasma cells become functional B-cells after antigen selection and islet cell precursors become functional islet cells which secrete insulin in response to glucose challenge.
  • Type I diabetes insulin-dependent diabetes
  • pancreas has lost its ability to secrete insulin due to autoimmune destruction of the insulin-secreting pancreatic beta cells.
  • blood sugar levels can still fluctuate significantly.
  • the elevated blood glucose levels lead to side reactions in which toxic products are formed, leading to serious complications including blindness, kidney disease, circulatory problems, nerve damage, and, ultimately, coma and death.
  • pancreatic transplant is another option; however, the availability of donor pancreases is very limited. In addition, this requires major surgery and is fraught with complications.
  • U.S. Patent No. 5,510,263 describes the expansion of fetal pig pancreatic isletlike cell clusters (ICCs) cultured in contact with an extracellular matrix produced by 804G or NBT-n rat bladder carcinoma cells.
  • U.S. Patent No. 5,681,587 discloses the successful passaging of adult pig and human islet cells in contact with the same extracellular matrices.
  • U.S. Patent No. 5,672,361 discloses the growth of islet cells on various non-rat extracellular matrix proteins, referred to as laminin 5.
  • International Publication No. PCT WO 97/16536 discloses co-culturing of freshly isolated, non- proliferated pancreatic islet cells with islet cells which have undergone proliferation.
  • One embodiment of the present invention is a method of inducing differentiation of cells having a passage number of one or greater, comprising contacting the cells with an effective differentiation-inducing amount of initially passaged (PO) cells of the same cell type to form reaggregated cells.
  • the cells are pancreatic islet cells.
  • the cells are fibroblasts, epithelial cells, endothelial cells, osteoblasts, chondrocytes, hepatocytes, myoblasts or nerve cells.
  • the effective amount of PO cells is between about 1% and 20%. More preferably, the effective amount of PO cells is between about 5% and about 10%.
  • the present invention also provides reaggregated cells produced by the method described above.
  • Another embodiment of the invention is a method for treating diabetes in a mammal in need thereof, comprising the step of administering to the mammal an effective insulin producing amount of the reaggregated islet cells described above.
  • the mammal is a human.
  • the administering step is by implantation under the kidney capsule or direct injection into the liver or peritoneal cavity.
  • the cells are placed in an immunoprotective barrier prior to the administering step.
  • the present invention also provides the use of the reaggregated islet cells described above in the preparation of a medicament for treatment of diabetes.
  • Figures 1A-1C are graphs showing the glucose responsiveness of expanded porcine fresh islets (Fig. 1 A), PO pseudoislets (Fig. IB) and P4* islets obtained by co- aggregation of 90% P4 cells with 10% P0 cells (Fig. 1C).
  • the reaggregated "pseudoislets” respond to changes in glucose concentration by secreting insulin in a manner similar to that of freshly isolated islets.
  • pancreatic islet cells ⁇ Pl
  • PO initially expanded
  • PO cells are defined as cells isolated from a tissue or organ which have been initially cultured and expanded in vitro, but have not been passaged in culture. Typically, these PO cells exhibit an expansion (increase in cell number) of about 10- fold.
  • the term "passaging" indicates that the PO cells have been initially expanded, removed from their tissue culture dish or flask with trypsin, and reseeded into another dish or flask. The trypsinized, replated cells are referred to as PI cells. This procedure is then repeated to obtain P2, P3, ...PX cells. However, when cells are passaged in culture, they gradually lose their specialized functions and become less differentiated (dedifferentiated).
  • pancreatic islet cells when freshly isolated, fully differentiated pancreatic islet cells are passaged in culture, they gradually lose their ability to secrete insulin in response to a glucose challenge. Due to the batch-to-batch variability associated with the use of freshly isolated cells, there is a significant advantage to the use of initially expanded PO cells for inducing differentiation of cells passaged to PI or later passages. Because PO cells have already undergone some dedifferentiation, they afford a greater level of experimental control than do freshly isolated cells. In a preferred embodiment, the amount of initially expanded PO cells added to expanded cells is between about 1% and 20%. In a more preferred embodiment, the amount of PO cells is between about 5% and about 10%.
  • cytokeratins 7 and 20 markers for ductal cell types which are considered to represent the proliferation compartment in the adult pancreas.
  • the passaged cells gradually lose expression of islet cell markers including insulin, glucagon, somatostatin and GLUT-2, suggesting that they become less differentiated.
  • the P0 cells promote restoration of endocrine function in the resulting "pseudoislets.”
  • Cells within these "pseudoislets” express insulin as assessed by immunofluorescence microscopy and enzyme linked immunosorbent assay (ELISA). In addition, they respond to changes in glucose levels by secreting insulin in a manner similar to freshly isolated islet cells.
  • ELISA enzyme linked immunosorbent assay
  • any cell type which has undergone one or more passages in culture by addition of the corresponding PO cells is also within the scope of the invention.
  • Such cell types include, but are not limited to, fibroblasts, epithelial cells, endothelial cells, osteoblasts, chondrocytes, hepatocytes, myoblasts and nerve cells.
  • the amount of corresponding PO cells required for differentiation a particular passaged cell type can be determined by one of ordinary skill in the art by routine experimentation.
  • pancreatic islet cells can be isolated, passaged and induced to reaggregate and differentiate by the method described above, then implanted into a diabetic mammal, preferably a human.
  • hepatocytes can be isolated, expanded and induced to reaggregate ex vivo by addition of initially passaged (PO) hepatocytes.
  • PO passaged
  • the reaggregated hepatocytes can be implanted into an individual having a liver disorder.
  • Either autologous or heterologous human islet cells can be used to obtain reaggregated differentiated cells for human transplantation.
  • nonhuman, preferably porcine, islet cells can be used. If heterologous human or nonhuman cells are used, it is desirable to place the cells in an immunoprotective barrier prior to transplantation thereof due to potential rejection by the host immune system.
  • Porcine islet cells were cultured and expanded as described in the following example.
  • Pancreatic islet cells were isolated from Yucatan minipigs (Kenmochi et al., Transplant Proc, 26:3424, 1994). Islets were expanded using conventional tissue culture techniques on flasks coated with purified laminin 5 as described in U.S. Patent
  • DAPI 4,6-diamino-2- phenylindole
  • Intracellular or secreted insulin was measured by a standard enzyme immunoassay (e.g., insulin enzyme immunoassay kit from Peninsula Laboratories).
  • a standard enzyme immunoassay e.g., insulin enzyme immunoassay kit from Peninsula Laboratories.
  • reaggregated "pseudoislets” were subjected to sequential treatment with low (3 mM) glucose, high (16.5 mM) glucose, low glucose, high glucose containing 10 mM theophylline, and finally low glucose.
  • the glucose response is summarized in Figures 1A-1C which indicate that the "pseudoislets" respond to changes in glucose concentration by secreting insulin in a manner similar to that of freshly isolated islets.
  • the fold-expansion and insulin content of the fresh islets, PO, P4 and P7 cells are summarized in Table 1, both in cell monolayers and aggregates.
  • P4 and P7 islet cells were incubated with initially passaged (P0) cells in a ratio of 9:1. and insulin content was determined. Unexpectedly, the P0 cells promoted differentiation of the P4 and P7 cells as shown by the ability of the reaggregated cells to produce insulin (Table 1). In contrast, the P7 cells alone produced no insulin. The vast majority of the insulin produced was due to the P7 cells, not the PO cells. As shown in Table 1, PO islet cell aggregates produced 7.08 ng insulin. Thus, the combination of 90% P7 cells, which produce no insulin, with 10% PO cells, which would be expected to produce only 0.708 ng insulin, would be expected to produce only 0.708 ng insulin. However, the combination unexpectedly yielded 2.46 ng insulin, over four times the expected amount.
  • P0 cells can induce differentiation of P3, P5, P6 and P8 cells which regain the ability to secrete insuhn in response to glucose challenge. It is contemplated that P0 cells can induce differentiation of any passaged cell population in a less differentiated state ( > P 1 ) .
  • the "pseudoislet” aggregates produced by the method of the present invention are transplanted into a diabetic mammal, preferably a human.
  • the aggregated islet cells are implanted under the kidney capsule or injected directly into the liver.
  • the cells are preferably placed in an immunoprotective barrier, such as a permselective membrane, prior to implantation to prevent destruction by the immune system of the mammal into which they are implanted.
  • Example 3 Transplantation of reaggregated islet cells into diabetic patients
  • Human diabetes patients are administered between about 10 5 and 10 6 islet cells prepared in accordance with Example 2, either by implantation under the kidney capsule or by direct injection into the liver.
  • transplantation in other ectopic organ locations is also contemplated. Blood glucose levels are monitored over several months and are significantly lower than prior to cellular implantation.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un procédé provoquant la différenciation de cellules ayant subi plusieurs passages moins différenciées en les mettant en contact avec des cellules du même type ayant subi initialement plusieurs passages (P0) et plus différenciées. Le procédé produit des agrégats de cellules différenciées tels que des agrégats de cellules d'îlots de Langherans utilisables pour des transplantations.
EP99928354A 1998-05-29 1999-05-28 Promotion de la differenciation cellulaire par des cellules ayant subi initialement plusieurs passages Withdrawn EP1080183A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8768598A 1998-05-29 1998-05-29
US87685 1998-05-29
PCT/US1999/011949 WO1999061586A1 (fr) 1998-05-29 1999-05-28 Promotion de la differenciation cellulaire par des cellules ayant subi initialement plusieurs passages

Publications (1)

Publication Number Publication Date
EP1080183A1 true EP1080183A1 (fr) 2001-03-07

Family

ID=22206656

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99928354A Withdrawn EP1080183A1 (fr) 1998-05-29 1999-05-28 Promotion de la differenciation cellulaire par des cellules ayant subi initialement plusieurs passages

Country Status (5)

Country Link
EP (1) EP1080183A1 (fr)
AU (1) AU4544299A (fr)
CA (1) CA2333702A1 (fr)
IL (1) IL139883A0 (fr)
WO (1) WO1999061586A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759039B2 (en) 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
US7101546B2 (en) 2001-12-21 2006-09-05 Amcyte, Inc. In situ maturation of cultured pancreatic stem cells having a specified, intermediate stage of development

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273039A4 (fr) * 1986-04-03 1990-01-08 Univ East Carolina Procede utilisant la capacite d'induction d'une matrice extracellulaire pour produire des tissus d'ilots pancreatiques.
US5510263A (en) * 1993-04-05 1996-04-23 Desmos, Inc. Growth of pancreatic islet-like cell clusters
JPH11507047A (ja) * 1995-06-06 1999-06-22 ケース ウエスターン リザーブ ユニバーシティ ヒト間葉幹細胞の筋原性分化
US5681587A (en) * 1995-10-06 1997-10-28 Desmos, Inc. Growth of adult pancreatic islet cells
AU7443996A (en) * 1995-10-30 1997-05-22 Vivorx, Inc. Method for ex vivo proliferation and differentiation of adult pancreatic islet cells, media useful therefor and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9961586A1 *

Also Published As

Publication number Publication date
WO1999061586A1 (fr) 1999-12-02
CA2333702A1 (fr) 1999-12-02
WO1999061586A9 (fr) 2000-04-27
WO1999061586A8 (fr) 2000-03-09
IL139883A0 (en) 2002-02-10
AU4544299A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
AU781750B2 (en) Platform for the differentiation of cells
KR100374976B1 (ko) 기능성랑게르한스섬의시험관내성장및그생체내사용방법
EP1326968B1 (fr) Systeme de culture et de recolte tridimensionnel non perturbateur pour cellules dependantes d'un support
JP5263756B2 (ja) 細胞の培養方法および細胞培養物
US20120121553A1 (en) Selection and propagation of progenitor cells
CN112980771B (zh) 一种制备胰腺beta细胞的方法及其应用
KR20200018506A (ko) 세포 대체 요법을 제공하기 위한 조성물 및 방법
JPH11514877A (ja) 機能性ランゲルハンス島のインビトロ成長およびそのインビボの使用
US20050037490A1 (en) Medium for preparing dedifferentiated cells
US20040033599A1 (en) Medium for preparing dedifferentiated cells
US20240124843A1 (en) Functional feline pancreatic cells from adipose tissue
US20010000324A1 (en) Promotion of cell differentiation by initially passaged cells
Schrezenmeir et al. Long-term function of porcine islets and single cells embedded in barium-alginate matrix
WO2003066832A2 (fr) Generation de nouvelles cellules d'insuline a partir de cellules souches presentes dans des ilots pancreatiques adultes
EP1080183A1 (fr) Promotion de la differenciation cellulaire par des cellules ayant subi initialement plusieurs passages
JP2000139455A (ja) ランゲルハンス島の培養及び島自己移植島再生方法
WO1997039107A2 (fr) Procede permettant d'accelerer la maturation des cellules
WO2001032839A2 (fr) Milieu servant a la preparation de cellules dedifferenciees
US6562620B2 (en) Medium to promote islet cell survival
Yagi et al. Stimulative effect of non-parenchymal liver cells on ability of tyrosine aminotransferase induction in hepatocytes
KR100354931B1 (ko) 췌도의 대량 배양증식 및 증식한 췌도에 의한 당뇨치료방법
US20070009882A1 (en) In vitro platform for screening agents inducing islet cell neogenesis
US20080069890A1 (en) Method for treating patients with implants of islets which have been kept in long term, in vitro culture
WO1999015625A1 (fr) Milieu favorisant la survie des cellules insulaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010308